Literature DB >> 2106390

Glucocorticoid effects on myeloma cells in culture: correlation of growth inhibition with induction of glucocorticoid receptor messenger RNA.

M Gomi1, K Moriwaki, S Katagiri, Y Kurata, E B Thompson.   

Abstract

Glucocorticoids are widely used for the treatment of multiple myeloma. To investigate the direct actions of glucocorticoids on myeloma cells, we have used three cell lines of human multiple myeloma, OPM-1, OPM-2, and RPMI 8226. When growth curves of these cells were examined, OPM-1 cells were resistant, while OPM-2 were sensitive to dexamethasone (DEX). In cultures of OPM-2 cells, addition of DEX led to virtual cessation of growth, with only 16% of the residual cells viable after 4 days. RPMI 8226 appeared to be slightly sensitive, showing some slowing of growth for several days in DEX, with later recovery. Viabilities of OPM-1 and RPMI 8226 cells were not affected. Secretion of immunoglobulin (Ig-lambda) was also partially suppressed, by 30% in OPM-2 and 14% in OPM-1. No significant suppression was observed in RPMI 8226. To explore the mechanism of these differential responses to the steroid, glucocorticoid receptor (GR) was examined. Binding assays showed high affinity binding sites in all three cell lines: 64 +/- 11 fmol/10(6) cells in OPM-1, 78 +/- 14 in OPM-2, and 62 +/- 16 in RPMI 8226. Nuclear transfer of GR and DNA-cellulose binding after heat activation appeared similar in all three cell lines. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of cytosol proteins labeled with [3H]dexamethasone mesylate showed a GR of Mr 95,000 in all three. When GR mRNA was studied in these cells, all of them had GR mRNA of approximately 7 kilobases, but OPM-2 and RPMI 8226 had 3 times more GR mRNA than OPM-1. OPM-2 GR mRNA was induced 2-fold by DEX treatment at 5 x 10(-9) M or greater. OPM-1 GR mRNA was much less sensitive, with no response at less than 10(-6) M DEX and only 1.5-fold induction at that concentration. These results demonstrate that some myeloma cells can be killed by a direct action of glucocorticoids. The quantity and affinity of GR in the cells were not predictive of this response. Therefore, we propose that the resistance of OPM-1 and the relative resistance of RPMI 8226 to glucocorticoid inhibition of cell growth is by post-receptor mechanisms. The high sensitivity of induction of GR mRNA in OPM-2 may correlate with glucocorticoid-evoked cell kill.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2106390

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Glucocorticoid receptor knock down reveals a similar apoptotic threshold but differing gene regulation patterns in T-cell and pre-B-cell acute lymphoblastic leukemia.

Authors:  Jason R Schwartz; Purvaba J Sarvaiya; Wayne V Vedeckis
Journal:  Mol Cell Endocrinol       Date:  2010-02-17       Impact factor: 4.102

2.  Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.

Authors:  Laurence Catley; Ellen Weisberg; Tanyel Kiziltepe; Yu-Tzu Tai; Teru Hideshima; Paola Neri; Pierfrancesco Tassone; Peter Atadja; Dharminder Chauhan; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

3.  HPAC, a new human glucocorticoid-sensitive pancreatic ductal adenocarcinoma cell line.

Authors:  W R Gower; R M Risch; C V Godellas; P J Fabri
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-03       Impact factor: 2.416

4.  BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Authors:  Jake E Delmore; Ghayas C Issa; Madeleine E Lemieux; Peter B Rahl; Junwei Shi; Hannah M Jacobs; Efstathios Kastritis; Timothy Gilpatrick; Ronald M Paranal; Jun Qi; Marta Chesi; Anna C Schinzel; Michael R McKeown; Timothy P Heffernan; Christopher R Vakoc; P Leif Bergsagel; Irene M Ghobrial; Paul G Richardson; Richard A Young; William C Hahn; Kenneth C Anderson; Andrew L Kung; James E Bradner; Constantine S Mitsiades
Journal:  Cell       Date:  2011-09-01       Impact factor: 41.582

5.  MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies.

Authors:  Ronit Vogt Sionov
Journal:  ISRN Hematol       Date:  2013-01-29

6.  The promoter and first, untranslated exon of the human glucocorticoid receptor gene are GC rich but lack consensus glucocorticoid receptor element sites.

Authors:  J Zong; J Ashraf; E B Thompson
Journal:  Mol Cell Biol       Date:  1990-10       Impact factor: 4.272

7.  Characterization of the Glucocorticoid Receptor in Children Undergoing Cardiac Surgery.

Authors:  Saul Flores; David S Cooper; Amy M Opoka; Ilias Iliopoulos; Sarah Pluckebaum; Matthew N Alder; Kelli A Krallman; Rashmi D Sahay; Lin Fei; Hector R Wong
Journal:  Pediatr Crit Care Med       Date:  2018-08       Impact factor: 3.624

8.  Dual regulation of glucocorticoid-induced leucine zipper (GILZ) by the glucocorticoid receptor and the PI3-kinase/AKT pathways in multiple myeloma.

Authors:  Katharine D Grugan; Chunguang Ma; Seema Singhal; Nancy L Krett; Steven T Rosen
Journal:  J Steroid Biochem Mol Biol       Date:  2008-04-20       Impact factor: 4.292

9.  Dexamethasone reverses glucocorticoid receptor RNA depression in multi-drug resistant (MDR) myeloma cell lines.

Authors:  L Danel-Moore; M Brönnegard; J A Gustafsson
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

10.  A conserved molecular mechanism is responsible for the auto-up-regulation of glucocorticoid receptor gene promoters.

Authors:  Chuan-dong Geng; Jason R Schwartz; Wayne V Vedeckis
Journal:  Mol Endocrinol       Date:  2008-10-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.